Beren Therapeutics' Adrabetadex Shows 10-Year Neurological Preservation in Infantile-Onset NPC

  • Beren Therapeutics presented new data showing adrabetadex preserved neurological function for over 10 years in children with infantile-onset NPC.
  • Case study of two sisters demonstrated benefits of early treatment, with one sister starting treatment 10 months after symptom onset and the other starting 4 years after.
  • Additional data showed improved survival and slower disease progression with adrabetadex treatment.
  • FDA assigned a PDUFA target action date of November 17, 2026, for adrabetadex's NDA.

Beren Therapeutics' long-term data on adrabetadex represents a significant milestone in the treatment of infantile-onset NPC, a rare and devastating neurodegenerative disease. The preservation of neurological function for over a decade highlights the potential of cyclodextrin-based therapeutics to address the underlying cause of NPC. The strategic focus on early diagnosis and treatment initiation could set a new standard for managing this condition, with implications for other rare diseases characterized by defective cholesterol trafficking.

Regulatory Approval
Whether the FDA will approve adrabetadex by the November 17, 2026 PDUFA date, given the long-term data presented.
Treatment Paradigm
How adrabetadex will be integrated with other NPC treatments like arimoclomol and N-acetyl-L-leucine in clinical practice.
Market Potential
The pace at which Beren Therapeutics can expand access to adrabetadex for other forms of NPC beyond infantile-onset.